Original articleGrowth of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
Section snippets
Methods
The CATT cohort and methods have been described.8, 9, 10, 11 The CATT cohort consisted of 1185 patients with AMD and untreated choroidal/retinal neovascularization (CNV) with the CNV or its sequelae, such as intraretinal fluid, subretinal fluid, serous pigment epithelial detachment, hemorrhage, or blocked fluorescence, involving the foveal center. Patients were enrolled at 43 clinical centers in the United States between February 2008 and December 2009. Inclusion criteria included age ≥50 years
Results
Among 1185 participants, 86 (7.3%) had GA at baseline, 120 (10.1%) developed GA during year 1, and 36 (3.0%) developed GA during year 2 (Fig 1). Among the participants with GA, growth of GA could be determined from 2 or more visits in 81 prevalent cases and in 113 cases in whom GA was detected in year 1. Among these patients, 151 had blood drawn for genetic analysis.
Characteristics of prevalent and incident GA were generally similar, as shown in Table 1. Mean number of GA lesions was 2.06
Discussion
The overall GA growth rate in CATT, expressed as a square root transformation, was 0.43 (0.03) mm/year. This was similar to the square root transformed rate in 2 recent studies of dry AMD. Domalpally et al18 reported a growth rate of 0.4 mm/year in 593 Age-Related Eye Disease Study eyes with GA (mean baseline area, 3.17 mm2 [SE, 0.19]), and Yehoshua et al19 reported a growth rate of 0.37 mm/year in a small clinical trial of 30 patients with AMD (mean baseline area of 4.4 mm2 [SE, 0.81]).
References (30)
- et al.
Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials
Ophthalmology
(2011) - et al.
Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials
Ophthalmology
(2012) - et al.
Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials
Ophthalmology
(2013) - et al.
Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials
Ophthalmology
(2014) - et al.
Optical coherence tomography grading reproducibility during the Comparison of Age-Related Macular Degeneration Treatments Trials
Ophthalmology
(2012) - et al.
Pharmacogenetics for genes associated with age-related macular degeneration (AMD) in the Comparison of AMD Treatments Trials (CATT)
Ophthalmology
(2013) - et al.
Dietary omega-3 fatty acids, other fat intake, genetic susceptibility, and progression to incident geographic atrophy
Ophthalmology
(2013) - et al.
Circularity index as a risk factor for progression of geographic atrophy
Ophthalmology
(2013) - et al.
Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration. The COMPLETE Study
Ophthalmology
(2014) - et al.
Incidence and progression of geographic atrophy: observations from a population-based cohort
Ophthalmology
(2013)
The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials
Ophthalmology
Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States
Arch Ophthalmol
Ranibizumab for neovascular age-related macular degeneration
N Engl J Med
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
N Engl J Med
Optical coherence tomography after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration
Ophthalmic Surg Lasers Imaging
Cited by (0)
∗Supplemental material is available at www.aaojournal.org.
Financial Disclosure(s): The author(s) have made the following disclosure(s):
G.Y.: Biostatistical consultant – Janssen Research and Development, LLC.
Supported by cooperative agreements U10 EY017823, U10 EY017825, U10 EY017826, and U10 EY017828 from the National Eye Institute, National Institutes of Health, Department of Health and Human Services. www.clinicaltrials.gov identifier, NCT00593450.
- ∗
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group listed in Appendix 1 (available at www.aaojournal.org).